1 UST College of Science Department of Biological Sciences

Total Page:16

File Type:pdf, Size:1020Kb

1 UST College of Science Department of Biological Sciences UST College of Science Department of Biological Sciences 1 Pharmacogenomics of Myofascial Pain Syndrome An Undergraduate Thesis Submitted to the Department of Biological Sciences College of Science University of Santo Tomas In Partial Fulfillment of the Requirements for the Degree of Bachelor of Science in Biology Jose Marie V. Lazaga Marc Llandro C. Fernandez May 2021 UST College of Science Department of Biological Sciences 2 PANEL APPROVAL SHEET This undergraduate research manuscript entitled: Pharmacogenomics of Myofascial Pain Syndrome prepared and submitted by Jose Marie V. Lazaga and Marc Llandro C. Fernandez, was checked and has complied with the revisions and suggestions requested by panel members after thorough evaluation. This final version of the manuscript is hereby approved and accepted for submission in partial fulfillment of the requirements for the degree of Bachelor of Science in Biology. Noted by: Asst. Prof. Marilyn G. Rimando, PhD Research adviser, Bio/MicroSem 602-603 Approved by: Bio/MicroSem 603 panel member Bio/MicroSem 603 panel member Date: Date: UST College of Science Department of Biological Sciences 3 DECLARATION OF ORIGINALITY We hereby affirm that this submission is our own work and that, to the best of our knowledge and belief, it contains no material previously published or written by another person nor material to which a substantial extent has been accepted for award of any other degree or diploma of a university or other institute of higher learning, except where due acknowledgement is made in the text. We also declare that the intellectual content of this undergraduate research is the product of our work, even though we may have received assistance from others on style, presentation, and language expression. Jose Marie V. Lazaga Marc Llandro C. Fernandez Date: May 6, 2021 Date: May 6, 2021 Asst. Prof. Marilyn G. Rimando, PhD Research adviser Date: May 6, 2021 UST College of Science Department of Biological Sciences 4 ABSTRACT Myofascial pain syndrome (MPS) is a musculoskeletal pain condition characterised by localized deep pains in the skeletal muscle and fascia, known as trigger points. It is a top contributor to global disability, with a lifetime prevalence of up to 85%, increasing the rate of other health-related concerns. Some of the current pharmacological treatment modalities for MPS and other musculoskeletal pain (MSP)-related conditions show some favourable outcomes in pain. The genetic make-up of patients however may affect drug treatment response. Also, signalling cascades are affected due to the adverse gene-drug- drug-gene interactions. The signalling cascades of G-proteins, such as in cAMP pathway, are also highly linked to MPS and other diseases and conditions, which often present chronic pain complications. A secondary analysis systematic review, using structured mining was conducted to determine the top genes, drugs, and conditions associated with MPS. The data sets surveyed were sourced from several databases including Comparative Toxicogenomics Database (CTD) and GeneCards Suite Databases (GeneCards, MalaCards, PathCards). The purpose of this review is to provide information on the current knowledge on the pharmacogenomics of MPS to direct the focus of future studies to disease-gene-drug associations for better patient treatment and intervention outcomes. Further studies are necessary to better improve the quality of life of patients with MPS, including the minimisation of adverse drug reactions and maximisation of drug efficacy. Keywords: chronic pain, myofascial pain syndrome, pharmacogenomics UST College of Science Department of Biological Sciences 5 INTRODUCTION Chronic pain (Institute of Medicine (IoM), 2011) is amongst the most reported medical conditions in adults (Interagency Pain Research Coordinating Committee (IPRCC), 2016). Approximately 70% to 80% of patients with chronic pain have chronic musculoskeletal pain (MSP) disorder as the underlying diagnosis (James et al., 2018). Chronic MSP conditions are the top contributors to global disability, increasing the rate of other health-related concerns, including anxiety and depression, and opioid dependence (Cieza et al., 2020; Gatchel & Schultz, 2014; Groves et al., 1998; Ho et al., 2018; IoM, 2011; Hutson & Ward, 2015; IPRCC, 2016; James et al., 2018; Mills et al., 2019; Smith et al., 2001). Numerous treatment interventions are used in chronic pain management, including pharmacologic treatment modalities, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants (Gatchel & Schultz, 2014; Groves et al., 1998; Ho et al., 2018; Hutson & Ward, 2015), and non-pharmacologic treatment modalities, such as rehabilitation interventions (Gatchel & Schultz, 2014; Kamper et al., 2015). Myofascial Pain Syndrome Myofascial pain syndrome (MPS) is one of the common MSP conditions, described as localised deep pains and “complex of sensory, motor, and autonomic symptoms” in the skeletal muscle and fascia, caused by myofascial trigger points (MTrPs) (Friction et al., 1985; Gatchel & Schultz, 2014; Hutson & Ward, 2015; Kamper et al., 2015; Simons, 1975). Simons (1975) referred to MTrPs as “spots of exquisite tenderness and hyperirritability in muscles or their fascia, localised in taut, palpable bands”. MPS also presents neurologic and otologic associations, including muscle weakness, paraesthesia, UST College of Science Department of Biological Sciences 6 and hampered vision (Friction et al., 1985; Hutson & Ward, 2015; Simons, 1975). Due to the clinical similarities between MPS and other MSP conditions, most esp. fibromyalgia syndrome (FMS), it is postulated that later stages of MPS result in FMS (Friction et al., 1985; Gatchel & Schultz, 2014; Hutson & Ward, 2015; Simons, 1975). Prevalence of MPS The existing literature regarding the exact prevalence of MPS has been exceedingly rare (Tantanatip & Chang, 2020). A cross-sectional study conducted by Fleckenstein et al. (2010) reported that MPS has a lifetime prevalence of up to 85% amongst the general population, primarily affecting sedentary individuals (Vazquez-Delgado et al., 2009) and has a positive age correlation, with peak age prevalence between 59 to 74 years old (Bergman et al., 2001). There are no reports of significant differences in presentation between males and females. However, it is described that MPS is more prevalent in females than in males (Vazquez-Delgado et al., 2009; Galasso et al., 2020), but the difference was also not of statistical significance (Wolfe et al., 2013). MPS is the leading diagnosis of chronic and persistent localised pain in pain management clinics, with a prevalence of up to 90% (Fleckenstein et al., 2010). Aetiology and Pathophysiology of MPS The exact developmental mechanisms of MTrPs are unknown, but it is believed to be initiated by systemic or ergonomic factors, including gross or repetitive muscle trauma and psychological stress (Borg-Stein & Iaccarino, 2014; Gatchel & Schultz, 2014; Hutson & Ward, 2015; Orhan et al., 2018; Schneider, 1995; Tantanatip & Chang, 2020). Most common factors include fatigue, improper posture, osteoarthritis, and hypothyroidism. An UST College of Science Department of Biological Sciences 7 increased rate of acetylcholine synthesis, which, in turn, increases the activity of neuromuscular junctions occurs as a physiological response to physical muscle trauma and leads to a cascade of other biochemical responses, such as the release of vasoactive and inflammatory factors (Borg-Stein & Iaccarino, 2014; Hutson & Ward, 2015; Schneider, 1995; Shah et al., 2008; Tantanatip & Chang, 2020). The results of the trial conducted by Srbely et al. (2010) implied that neurogenic inflammation could facilitate the formation of MTrPs even in the absence of localised muscle injury. Combined evidence (Smith & Haythornthwaite, 2004) of longitudinal and micro longitudinal studies suggests that sleep disturbance exacerbates MPS. The main mechanistic hypothesis put forth in describing MPS is central sensitisation (Hocking, 2013; Hutson & Ward, 2015; Latremoliere & Woolf, 2009; Tantanatip & Chang, 2020), such as hyperalgesia and allodynia, and characterised by a pain persisting for more than three months (Hutson & Ward, 2015; Rivers et al., 2015; Tantanatip & Chang, 2020). However, various hypotheses surrounding chronic MSP conditions are being stipulated. This considers MSP disorders, such as MPS, a biopsychosocial condition, wherein biological, psychological, and social factors significantly affect the belief, behaviour, and cognition towards pain (Orhan et al., 2018). Diagnosis Travell and D. G. Simons (1983; … L.S Simons, 1999) proposed the initial set of diagnostic criteria for MPS. The primary diagnostic features of MPS include patterned localised pain, palpable taut band and focal tenderness within it, restricted locomotion in the pain region, and weakness without atrophy. The secondary criteria involve chief pain UST College of Science Department of Biological Sciences 8 complaints after applied pressure on MTrP nodules, generation of local twitch response upon introduction of snapping palpation and diminishing or relief from pain following muscular treatment. Despite the origination of this diagnostic manual defining clear signs and symptoms, there is yet to be a uniformly accepted diagnostic protocol for the diagnosis of MPS. One of diagnostic challenges is the poor reliability in detecting taut bands (Hutson & Ward, 2015; Myburgh et al., 2008; Simons et al., 1999; Tough et al., 20017; Travel & Simons,
Recommended publications
  • Neuronal Pentraxin 2: a Synapse-Derived CSF Biomarker in Genetic Frontotemporal Dementia
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-322493 on 9 April 2020. Downloaded from Neurodegeneration ORIGINAL RESEARCH Neuronal pentraxin 2: a synapse- derived CSF biomarker in genetic frontotemporal dementia Emma L van der Ende ,1 Meifang Xiao,2 Desheng Xu,2 Jackie M Poos ,1 Jessica L Panman,1,3 Lize C Jiskoot ,1,4 Lieke H Meeter,1 Elise GP Dopper,1 Janne M Papma,1 Carolin Heller ,5 Rhian Convery ,4 Katrina Moore,4 Martina Bocchetta ,4 Mollie Neason,4 Georgia Peakman,4 David M Cash,4 Charlotte E Teunissen,6 Caroline Graff,7,8 Matthis Synofzik,9,10 Fermin Moreno,11 Elizabeth Finger ,12 Raquel Sánchez- Valle,13 Rik Vandenberghe,14 Robert Laforce Jr,15 Mario Masellis,16 Maria Carmela Tartaglia,17 James B Rowe ,18 Christopher R Butler,19 Simon Ducharme,20 Alex Gerhard,21,22 Adrian Danek,23 Johannes Levin,23,24,25 Yolande AL Pijnenburg,26 Markus Otto ,27 Barbara Borroni ,28 Fabrizio Tagliavini,29 Alexandre de Mendonca,30 Isabel Santana,31 Daniela Galimberti,32,33 Harro Seelaar,1 Jonathan D Rohrer,4 Paul F Worley,2,34 John C van Swieten ,1 on behalf of the Genetic Frontotemporal Dementia Initiative (GENFI) ► Additional material is ABSTRACT INTRODUCTION published online only. To view Introduction Synapse dysfunction is emerging as an Frontotemporal dementia (FTD), a common form please visit the journal online (http:// dx. doi. org/ 10. 1136/ early pathological event in frontotemporal dementia of early-onset dementia, has an autosomal dominant jnnp- 2019- 322493). (FTD), however biomarkers are lacking. We aimed inheritance in 20%–30% of patients, most often to investigate the value of cerebrospinal fluid (CSF) due to mutations in granulin (GRN), chromosome For numbered affiliations see neuronal pentraxins (NPTXs), a family of proteins 9 open reading frame 72 (C9orf72) or microtubule- end of article.
    [Show full text]
  • A Novel Approach to Identify Driver Genes Involved in Androgen-Independent Prostate Cancer
    Schinke et al. Molecular Cancer 2014, 13:120 http://www.molecular-cancer.com/content/13/1/120 RESEARCH Open Access A novel approach to identify driver genes involved in androgen-independent prostate cancer Ellyn N Schinke1, Victor Bii1, Arun Nalla1, Dustin T Rae1, Laura Tedrick1, Gary G Meadows1 and Grant D Trobridge1,2* Abstract Background: Insertional mutagenesis screens have been used with great success to identify oncogenes and tumor suppressor genes. Typically, these screens use gammaretroviruses (γRV) or transposons as insertional mutagens. However, insertional mutations from replication-competent γRVs or transposons that occur later during oncogenesis can produce passenger mutations that do not drive cancer progression. Here, we utilized a replication-incompetent lentiviral vector (LV) to perform an insertional mutagenesis screen to identify genes in the progression to androgen-independent prostate cancer (AIPC). Methods: Prostate cancer cells were mutagenized with a LV to enrich for clones with a selective advantage in an androgen-deficient environment provided by a dysregulated gene(s) near the vector integration site. We performed our screen using an in vitro AIPC model and also an in vivo xenotransplant model for AIPC. Our approach identified proviral integration sites utilizing a shuttle vector that allows for rapid rescue of plasmids in E. coli that contain LV long terminal repeat (LTR)-chromosome junctions. This shuttle vector approach does not require PCR amplification and has several advantages over PCR-based techniques. Results: Proviral integrations were enriched near prostate cancer susceptibility loci in cells grown in androgen- deficient medium (p < 0.001), and five candidate genes that influence AIPC were identified; ATPAF1, GCOM1, MEX3D, PTRF, and TRPM4.
    [Show full text]
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • Anti-ARL4A Antibody (ARG41291)
    Product datasheet [email protected] ARG41291 Package: 100 μl anti-ARL4A antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes ARL4A Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P Host Rabbit Clonality Polyclonal Isotype IgG Target Name ARL4A Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 121-200 of Human ARL4A (NP_001032241.1). Conjugation Un-conjugated Alternate Names ARL4; ADP-ribosylation factor-like protein 4A Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 23 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol ARL4A Gene Full Name ADP-ribosylation factor-like 4A Background ADP-ribosylation factor-like 4A is a member of the ADP-ribosylation factor family of GTP-binding proteins. ARL4A is similar to ARL4C and ARL4D and each has a nuclear localization signal and an unusually high guaninine nucleotide exchange rate.
    [Show full text]
  • Microarray Analysis of Gene Expression in the Ovarian Cancer Cell Line HO-8910 with Silencing of the ZNF217 Gene
    MOLECULAR MEDICINE REPORTS 2: 851-855, 2009 851 Microarray analysis of gene expression in the ovarian cancer cell line HO-8910 with silencing of the ZNF217 gene GUIQIN SUN1, JINGXIA QIN1, YUWEN QIU1, YUNFEI GAO1, YANHONG YU1, QINKAI DENG2 and MEI ZHONG1 1Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University; 2Department of Bioinformatics, Southern Medical University, Guangzhou 510515, Guangdong, P.R. China Received April 30, 2009; Accepted July 7, 2009 DOI: 10.3892/mmr_00000183 Abstract. Zinc-finger protein 217 (ZNF217), which is over- late stages (stage III or IV) and have a 5-year survival rate of expressed during cancer progression, can promote tumor cell less than 30% (1). Ovarian cancer is a heterogeneous disease immortalization. To examine the function of ZNF217, a global with respect to its histopathology, molecular biology and expression profile was carried out using Affymetrix Gene clinical outcome. Though studies on the etiology of ovarian Chip analysis with HG-U133 plus 2.0 arrays in the ovarian cancer and susceptibility to the disease have shown that the cancer cell line HO-8910 after silencing of the ZNF217 gene. mechanisms of carcinogenesis and cancer development are The results were analyzed using the Gene Ontology program associated with genetic, epigenetic and environmental factors, to investigate the functional network affected by ZNF217 the pathogenesis of ovarian cancer remains unclear (2). in ovarian cancer cells. Changes in the mRNA expression Among the current methods for the identification of gene of the affected genes were confirmed by real-time reverse expression profiles in cancer, microarray analysis is the most transcriptase-polymerase chain reaction (RT-PCR).
    [Show full text]
  • A Database for Human and Yeast Genes Involved in Telomere Maintenance Delia M
    Braun et al. BMC Genetics (2018) 19:32 https://doi.org/10.1186/s12863-018-0617-8 DATABASE Open Access TelNet - a database for human and yeast genes involved in telomere maintenance Delia M. Braun, Inn Chung, Nick Kepper, Katharina I. Deeg and Karsten Rippe* Abstract Background: The ends of linear chromosomes, the telomeres, comprise repetitive DNA sequences in complex with proteins that protects them from being processed by the DNA repair machinery. Cancer cells need to counteract the shortening of telomere repeats during replication for their unlimited proliferation by reactivating the reverse transcriptase telomerase or by using the alternative lengthening of telomeres (ALT) pathway. The different telomere maintenance (TM) mechanisms appear to involve hundreds of proteins but their telomere repeat length related activities are only partly understood. Currently, a database that integrates information on TM relevant genes is missing. Description: To provide a resource for studies that dissect TM features, we here introduce the TelNet database at http://www.cancertelsys.org/telnet/. It offers a comprehensive compilation of more than 2000 human and 1100 yeast genes linked to telomere maintenance. These genes were annotated in terms of TM mechanism, associated specific functions and orthologous genes, a TM significance score and information from peer-reviewed literature. This TM information can be retrieved via different search and view modes and evaluated for a set of genes as demonstrated for an exemplary application. Conclusion: TelNet supports the annotation of genes identified from bioinformatics analysis pipelines to reveal possible connections with TM networks. We anticipate that TelNet will be a helpful resource for researchers that study telomeres.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Primate Specific Retrotransposons, Svas, in the Evolution of Networks That Alter Brain Function
    Title: Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function. Olga Vasieva1*, Sultan Cetiner1, Abigail Savage2, Gerald G. Schumann3, Vivien J Bubb2, John P Quinn2*, 1 Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K 2 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK 3 Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, D-63225 Germany *. Corresponding author Olga Vasieva: Institute of Integrative Biology, Department of Comparative genomics, University of Liverpool, Liverpool, L69 7ZB, [email protected] ; Tel: (+44) 151 795 4456; FAX:(+44) 151 795 4406 John Quinn: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK, [email protected]; Tel: (+44) 151 794 5498. Key words: SVA, trans-mobilisation, behaviour, brain, evolution, psychiatric disorders 1 Abstract The hominid-specific non-LTR retrotransposon termed SINE–VNTR–Alu (SVA) is the youngest of the transposable elements in the human genome. The propagation of the most ancient SVA type A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after the chimpanzee divergence. Functional enrichment analysis of genes associated with SVA insertions demonstrated their strong link to multiple ontological categories attributed to brain function and the disorders. SVA types that expanded their presence in the human genome at different stages of hominoid life history were also associated with progressively evolving behavioural features that indicated a potential impact of SVA propagation on a cognitive ability of a modern human.
    [Show full text]
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short
    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Temporal Chip-On-Chip of RNA-Polymerase-II to Detect Novel Gene Activation Events During Photoreceptor Maturation
    Molecular Vision 2010; 16:252-271 <http://www.molvis.org/molvis/v16/a32> © 2010 Molecular Vision Received 12 July 2009 | Accepted 10 February 2010 | Published 17 February 2010 Temporal ChIP-on-Chip of RNA-Polymerase-II to detect novel gene activation events during photoreceptor maturation Padmaja Tummala, Raghuveer S. Mali, Eduardo Guzman, Xiao Zhang, Kenneth P. Mitton (The first two authors contributed equally to this work.) Eye Research Institute, Oakland University, Rochester, MI Purpose: During retinal development, post-mitotic neural progenitor cells must activate thousands of genes to complete synaptogenesis and terminal maturation. While many of these genes are known, others remain beyond the sensitivity of expression microarray analysis. Some of these elusive gene activation events can be detected by mapping changes in RNA polymerase-II (Pol-II) association around transcription start sites. Methods: High-resolution (35 bp) chromatin immunoprecipitation (ChIP)-on-chip was used to map changes in Pol-II binding surrounding 26,000 gene transcription start sites during photoreceptor maturation of the mouse neural retina, comparing postnatal age 25 (P25) to P2. Coverage was 10–12 kb per transcription start site, including 2.5 kb downstream. Pol-II-active regions were mapped to the mouse genomic DNA sequence by using computational methods (Tiling Analysis Software-TAS program), and the ratio of maximum Pol-II binding (P25/P2) was calculated for each gene. A validation set of 36 genes (3%), representing a full range of Pol-II signal ratios (P25/P2), were examined with quantitative ChIP assays for transcriptionally active Pol-II. Gene expression assays were also performed for 19 genes of the validation set, again on independent samples.
    [Show full text]
  • Submicroscopic Distribution of Ruthenium Red in Human Glioblastoma Multiforme*
    I. Neurosurg. / Volume 32 / February, 1970 Submicroscopic Distribution of Ruthenium Red in Human Glioblastoma Multiforme* WILLIAM BONDAREFF, M.D., PH.D. Department of Biostructure,. Northwestern University Medical School, Chicago, Illinois LECTRON microscope studies have forme is well documented,24 and more recent suggested the presence of a poly- electron microscope studies further demon- anionic intercellular substance in strate this complexity.8,11,13,18,19 The ultra- mammalian central nervous tissue. 3-6,~ The structure of the intercellular matrix of glio- composition of this material, which appears blastoma multiforme has not been described to occupy the extracellular space of the previously, but light microscope studies sug- brain, is not known, but chemical studies in- gest an intercellular matrix with staining dicate the presence of an acid mucopolysac- properties similar to those of connective charide. 2~ Its intercellular distribution has tissue. 11 been demonstrated by visualization in the electron microscope of electron-opaque Materials and Methods metal complexes (for example, of phospho- Specimens of nine suspected gliomas were tungstic acid '-'~ and ruthenium redO, but the obtained during operation at the Neurosurgi- relation of these complexes to plasma mem- cal Clinic, Sahlgrenska Hospital, Gothen- branes is obscured in central nervous tissue burg, Sweden. After surgical exposure of the by the sparsity of intercellular space. The di- neoplasm, a specimen was taken by sharp mensions of the extracellular space in brain dissection from an area thought not to be are not known with certainty, and the stain- necrotic. Electrocautery was avoided and able material localized within the intercellu- special care was exercised in the use of lar spaces may be either a plasma mem- clamps and hemostats.
    [Show full text]